Orion Pharma Limited reported consolidated earnings results for the year ended on June 30, 2017. The company has also reported consolidated EPS of BDT 3.40, Consolidated NAV per share (including Revaluation Surplus) of BDT 70.95 and Consolidated NOCFPS of BDT 9.62 for the year ended on June 30, 2017 as against BDT 5.65, BDT 69.99 and BDT 16.62 respectively for the year ended on June 30, 2016.